In-vitro binding assay study of Tc-99m-flouroquinolones with E. coli, Salmonella and Ps. aeruginosa

被引：3

作者：

Qadir, Muhammad Abdul ^{[1
]}

Wattoo, Feroza Hamid ^{[2
]}

Yaseen, Mehwish ^{[1
]}

Atta, Sadia ^{[1
]}

Wattoo, Muhammad Hamid Sarwar ^{[3
]}

Ahmad, Sheikh Asrar ^{[4
]}

Gulzar, Asad ^{[4
]}

机构：

[1] Univ Punjab, Inst Chem, Lahore 54590, Pakistan

[2] PMAS Arid Agr Univ, Univ Inst Biochem & Biotechnol, Rawalpindi, Pakistan

[3] Pakistan Inst Engn & Appl Sci, Ishfaq Ahmed Res Labs, Islamabad, Pakistan

[4] Univ Educ, Div Sci & Technol, Lahore, Pakistan

来源：

ALEXANDRIA JOURNAL OF MEDICINE | 2015年 / 51卷 / 01期

关键词：

Ciprofloxacin; Ofloxacin; Enorfloxacin; E; coli; Salmonella; Ps; aeruginosa;

D O I：

10.1016/j.ajme.2014.09.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A simple methodology was developed to evaluate binding efficiency of antibiotic members of fluoroquinolones, namely ciprofloxacin, ofloxacin and enorfloxacin, complexed with Tc-99m, against Escherichia coli, Salmonella and Pseudomonas aeruginosa bacterial strains. Radioactivity in the pellet, tips supernatant and micro-centrifugation tubes was counted separately for 5 s in a sodium iodide well-counter with dedicated nuclear medicine software. The overall percentage activity of the live and killed bacteria was found in the range of 5-46% with different types of labelled quinolones and bacteria. Activity of the labelled enorfloxacin and ciprofloxacin indicated acceptable results for both live and killed E. coli and Ps. aeruginosa. However, ofloxacin was found to be moderate for all the live bacterial stains. This developed methodology has achieved more than 95% labelling efficiency of Tc-99m with derivatized quinolones and also the observed results indicated that these complexes may be used as an infection specific imaging agents. (C) 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.

引用

页码：47 / 52

页数：6

共 16 条

[1]

Alexander K, 2005, CAN J VET RES, V69, P272

[2]

Benitez A, 2006, Q J NUCL MED MOL IM, V50, P147

[3] Radiopharmaceuticals to image infection and inflammation [J].